Volume 25, Issue 1, Pages (January 2017)

Slides:



Advertisements
Similar presentations
Date of download: 6/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Induction of Rapid and Highly Efficient Expression.
Advertisements

Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Up-regulation of Brain-Derived Neurotrophic Factor.
Foveal Hypoplasia in Patients with Stickler Syndrome
Volume 113, Issue 7, Pages 1187.e e12 (July 2006)
Microcystic Macular Edema
Correlation between Optical Coherence Tomography and Fluorescein Angiography Findings in Diabetic Macular Edema  Tomohiro Otani, MD, Shoji Kishi, MD 
Volume 17, Issue 4, Pages (April 2009)
Invest. Ophthalmol. Vis. Sci ;54(9): doi: /iovs Figure Legend:
From: Efficient Gene Transfer into Retinal Cells Using Adenoviral Vectors: Dependence on Receptor Expression Invest. Ophthalmol. Vis. Sci ;45(6):
From: Inflammatory Mediators Induced by Amyloid-Beta in the Retina and RPE In Vivo: Implications for Inflammasome Activation in Age-Related Macular Degeneration.
From: Deficiency of SHP-1 Protein-Tyrosine Phosphatase in “Viable Motheaten” Mice Results in Retinal Degeneration Invest. Ophthalmol. Vis. Sci ;47(3):
Volume 10, Pages (August 2016) Long-term outcomes of gene therapy for the treatment of Leber's hereditary optic neuropathy  Shuo Yang, Si-qi Ma,
Invest. Ophthalmol. Vis. Sci ;54(4): doi: /iovs Figure Legend:
Volume 5, Issue 6, Pages (June 2002)
Volume 3, Issue 5, Pages (May 2001)
Molecular Therapy - Methods & Clinical Development
Volume 122, Issue 7, Pages (July 2015)
From: Optical Coherence Tomography Angiography in Mice: Comparison with Confocal Scanning Laser Microscopy and Fluorescein Angiography Trans. Vis. Sci.
Volume 8, Issue 2, Pages (August 2003)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Volume 21, Issue 6, Pages (June 2013)
Volume 12, Issue 6, Pages (December 2005)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Figure 2 Optical coherence tomography of the human retina A) Detailed retinal segmentation sample on spectral-domain optical coherence tomography (OCT)
Optic neuritis: A mechanistic view
Activation of the Extracellular Signal-Regulated Kinase 1/2 Pathway by AAV Gene Transfer Protects Retinal Ganglion Cells in Glaucoma  Yu Zhou, Vincent.
Volume 4, Issue 5, Pages (May 2015)
Volume 22, Issue 2, Pages (February 2014)
Figure 1 Example OCT scan
Volume 21, Issue 10, Pages (October 2013)
Adeno-Associated Viral Vector-Mediated mTOR Inhibition by Short Hairpin RNA Suppresses Laser-Induced Choroidal Neovascularization  Tae Kwann Park, Si.
Molecular Therapy - Methods & Clinical Development
Volume 26, Issue 1, Pages (January 2018)
Molecular Therapy - Methods & Clinical Development
Volume 4, Issue 6, Pages (December 2001)
Volume 25, Issue 3, Pages (March 2017)
Volume 19, Issue 2, Pages (February 2011)
Volume 15, Issue 6, Pages (March 2005)
Choroidal neovascularization in transgenic mice expressing prokineticin 1: an animal model for age-related macular degeneration  Nobushige Tanaka, Masahito.
Volume 4, Issue 5, Pages (November 2001)
Molecular Therapy - Methods & Clinical Development
Volume 3, Issue 4, Pages (April 2001)
T.M. Alie, P.J. Vrljicak, D.B. Myburgh, I.R. Gupta 
Volume 11, Issue 3, Pages (September 2018)
Volume 5, Issue 6, Pages (June 2002)
Spatially and Temporally Regulated NRF2 Gene Therapy Using Mcp-1 Promoter in Retinal Ganglion Cell Injury  Kosuke Fujita, Koji M. Nishiguchi, Yukihiro.
Donna M. Martin, Yehoash Raphael  Molecular Therapy 
Volume 17, Issue 5, Pages (May 2009)
Volume 23, Issue 2, Pages (February 2015)
J. Fielding Hejtmancik, Xiaodong Jiao, Anren Li, Yuri V
Improved Retinal Transduction In Vivo and Photoreceptor-specific Transgene Expression Using Adenovirus Vectors With Modified Penton Base  Siobhan M Cashman,
Molecular Therapy - Methods & Clinical Development
Volume 17, Issue 12, Pages (December 2009)
Volume 13, Issue 3, Pages (March 2006)
Volume 8, Issue 2, Pages (August 2003)
Volume 18, Issue 3, Pages (March 2010)
The Lymphocytic Choriomeningitis Virus Envelope Glycoprotein Targets Lentiviral Gene Transfer Vector to Neural Progenitors in the Murine Brain  Colleen.
Volume 9, Issue 1, Pages (October 2014)
Volume 22, Issue 9, Pages (September 2014)
J.M.I. Malik, Z. Shevtsova, M. Bähr, S. Kügler  Molecular Therapy 
Volume 21, Issue 10, Pages (October 2013)
Morphological and functional evaluation of adult PGC-1–floxed mice 2 and 4 wk after subretinal AAV injection. Morphological and functional evaluation of.
Long-Term PEDF Release in Rat Iris and Retinal Epithelial Cells after Sleeping Beauty Transposon-Mediated Gene Delivery  Laura Garcia-Garcia, Sergio Recalde,
Volume 19, Issue 9, Pages (September 2011)
Volume 14, Issue 3, Pages (September 2006)
Figure 1 A B GCL NBL ED18.5 PND3 PND6 GCL
Volume 25, Issue 4, Pages (April 2017)
Volume 9, Issue 2, Pages (February 2004)
Long-Term PEDF Release in Rat Iris and Retinal Epithelial Cells after Sleeping Beauty Transposon-Mediated Gene Delivery  Laura Garcia-Garcia, Sergio Recalde,
Lindsey Weed, Michael J. Ammar, Shangzhen Zhou, Zhangyong Wei, Leona W
Presentation transcript:

Volume 25, Issue 1, Pages 296-302 (January 2017) Improved Intravitreal AAV-Mediated Inner Retinal Gene Transduction after Surgical Internal Limiting Membrane Peeling in Cynomolgus Monkeys  Kazuhisa Takahashi, Tsutomu Igarashi, Koichi Miyake, Maika Kobayashi, Chiemi Yaguchi, Osamu Iijima, Yoshiyuki Yamazaki, Yuko Katakai, Noriko Miyake, Shuhei Kameya, Takashi Shimada, Hiroshi Takahashi, Takashi Okada  Molecular Therapy  Volume 25, Issue 1, Pages 296-302 (January 2017) DOI: 10.1016/j.ymthe.2016.10.008 Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 1 Histological Analysis for Detection of GFP (A) Nineteen weeks after intravitreal injection of AAV, eyes were enucleated, sectioned, and stained for GFP. GFP expression was compared among a control group, group VIT (two eyes receiving VIT 1 month before AAV injection), and group VIT+ILM (two eyes receiving VIT and ILM peeling 1 month before AAV injection) at the macula and temporal fovea (1,500–2,000 μm temporal from the macula). White arrows indicate the RPE, which showed autofluorescence. Little GFP expression was detected in the control group or group VIT. Strong GFP expression was detected in group VIT+ILM (original magnification ×200; scale bar, 200 μm). (B) GFP expression areas (in pixels) were determined using ImageJ software and Photoshop software. The area of GFP expression in group VIT+ILM was broader than in the control group or group VIT. Molecular Therapy 2017 25, 296-302DOI: (10.1016/j.ymthe.2016.10.008) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 2 GFP Expression Was Limited to the ILM-Peeled Area Histological evaluation of GFP expression in the left eye of monkey 1, belonging to group VIT+ILM. (A) Periodic acid-Schiff staining (scale bar, 500 μm) and magnified images (original magnification ×400; scale bar, 100 μm). Red triangles indicate the boundaries of the ILM peeling. (B) Anti-GFP staining (scale bar, 500 μm). White triangles indicate the boundaries between strong and weak GFP expression areas. The location of strong GFP expression (flanked by white triangles) nearly matches the area of ILM peeling (flanked by red triangles). Magnified images of anti-GFP staining at the temporal fovea (left), macula (middle), and nasal fovea (1,000–1,500 μm nasal from the macula) (right) are shown. Original magnification ×400; scale bar, 100 μm. Nuclei were stained with DAPI. (C) Specific staining for Müller cells using an anti-glutamine synthetase (GS) antibody in the temporal fovea in group VIT+ILM (left). Anti-GFP staining is also shown (middle). The figures were merged using ImageJ software (right). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium. Molecular Therapy 2017 25, 296-302DOI: (10.1016/j.ymthe.2016.10.008) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 3 Comparison of Retinal Thickness throughout the Experimental Period Recorded Using Optical Coherence Tomography The OCT recorded at just prior to AAV vector injection (Pre-AAV); 1, 4, 8, and 12 weeks after AAV vector injection; and just prior to euthanasia (Pre-euthanasia). (A) OCT images recorded pre-AAV (upper row) and pre-euthanasia (lower row). (B) Retinal thickness was measured at the macula (α) and two para-foveal points (β, γ; 1,000 μm from the macular). Data from the two eyes in each group were averaged and plotted. Molecular Therapy 2017 25, 296-302DOI: (10.1016/j.ymthe.2016.10.008) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 4 Color Fundus Images and Fluorescein Angiography Images (A) Color fundus images of the left eye of monkey 3 (control) and the right and left eyes of monkey 1 (group VIT and group VIT+ILM, respectively). Images were obtained pre-AAV (upper row) and pre-euthanasia (lower row). (B) Fluorescein angiography images of the same three eyes obtained 13 weeks after AAV vector injection. Molecular Therapy 2017 25, 296-302DOI: (10.1016/j.ymthe.2016.10.008) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 5 Amplitudes of a- and b-Waves in Full-Field ERGs Full-field ERGs were recorded using the standard International Society for Clinical Electrophysiology of Vision (ISCEV) time course just prior to AAV vector injection (pre-AAV); 2, 3, 4, 6, 8, and 12 weeks after AAV vector injection; and just prior to euthanasia (pre-euthanasia). The ERG amplitudes in the two eyes from each group were averaged and plotted. (A) Amplitudes of b-waves in dark-adapted 0.01 full-field ERGs. (B and C) Amplitudes of a-waves (B) and b-waves (C) in dark-adapted 3.0 full-field ERGs. (D and E) Amplitudes of a-waves (D) and b-waves (E) in light-adapted 3.0 full-field ERGs. Molecular Therapy 2017 25, 296-302DOI: (10.1016/j.ymthe.2016.10.008) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions